Salvage Ultrahypofractionated Postoperative External Radiotherapy For Biochemical Recurrence

Status: Recruiting
Location: See location...
Intervention Type: Radiation
Study Type: Observational
SUMMARY

Recently, the Radiation Oncology Department at Fondazione IRCCS San Gerardo dei Tintori has been renovated and has been equipped with cutting edge technologies to treat prostate cancer. Specifically, the now available technology can track organ motion in real time, thus allowing improved precision in radiation delivery, with increased protection of the surrounding organs at risk. These facilities have already enabled the kickoff of two prospective observational trials, the ABRUPT and the POPART, which are currently ongoing in the treatment of intact prostate and the biochemical recurrence, respectively. Taken together, these observations provide the basis for the prospective clinical study herein proposed. Patients enrolled in the study will undergo salvage single stereotactic RT to the prostate bed by means of image guided volumetric intensity-modulated arc technique (IGRT-VMAT) and state-of-the-art treatment-planning and quality assurance procedures, with emphasis on normal tissue sparing and and pinpoint delivery accuracy via the use of devices that ensure stability and beam location reproducibility

Eligibility
Participation Requirements
Sex: Male
Minimum Age: 18
Maximum Age: 90
Healthy Volunteers: f
View:

• Subjects of male sex ≥ 18 years of age.

• Subjects have freely signed the pertinent informed consent before the beginning of the study

‣ Adenocarcinoma of the prostate treated with radical prostatectomy (any type of radical prostatectomy is permitted including retropubic, perineal, laparoscopic or robotically assisted; there is no time limit for the date of radical prostatectomy)

⁃ Detectable post-prostatectomy PSA of ≥ 0.1 - \< 2.0 ng/mL either (1) persistently detectable post-operatively or (2) developing biochemical recurrence after prostatectomy (initially undetectable)

⁃ No evidence of N1 and/or M1 disease assessed by PSMA PET-CT within 90 days prior to registration

⁃ Negative Magnetic Resonance Imaging (MRI) of the pelvis in case of equivocal evidence of local relapse on PSMA PET-CT

⁃ Androgen deprivation therapy (ADT) allowed as per physician's discretion

⁃ ECOG performance status of 0-1

⁃ Ability to complete the questionnaires

Locations
Other Locations
Italy
Radiation Oncology, Fondazione IRCCS San Gerardo dei Tintori (University of Milan Bicocca)
RECRUITING
Monza
Contact Information
Primary
Stefano Arcangeli, MD
stefano.arcangeli@unimib.it
+39 0392333663
Time Frame
Start Date: 2025-05-02
Estimated Completion Date: 2033-05
Participants
Target number of participants: 50
Related Therapeutic Areas
Sponsors
Leads: University of Milano Bicocca

This content was sourced from clinicaltrials.gov